Opendata, web and dolomites

FAITh SIGNED

Fighting Anxiety with Importin-based Therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FAITh project word cloud

Explore the words cloud of the FAITh project. It provides you a very rough idea of what is the project "FAITh" about.

modern    interesting    initial    drugs    efficacy    analogs    dependent    regulation    society    ip    signaling    treatment    deregulation    phenotyping    link    difficulty    functional    carry    molecular    diversity    synapse    leads    cell    behavioural    nucleus    disorders    importins    course    importin    hts    structural    grant    screen    final    repositioned    devise    transport    discovery    maximizing    drug    assay    potentially    receptor    vivo    suboptimal    validate    limited    presented    conduct    synaptic    erc    roles    variety    hence    therapeutic    levels    mutants    fraught    size    mutant    burden    commercialisation    tests    sensing    avenues    closely    compatible    line    phenotype    axonal    anxiety    poc    anxiolytic    additional    stress    either    pilot    contexts    protection    agents    molecules    neurotransmitter    approved    follow    200    date    physiological    anxiolysis    identifications    mechanisms    rendering    compounds    health    mouse    discovered    modulate    injury   

Project "FAITh" data sheet

The following table provides information about the project.

Coordinator
WEIZMANN INSTITUTE OF SCIENCE 

Organization address
address: HERZL STREET 234
city: REHOVOT
postcode: 7610001
website: www.weizmann.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2019-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) coordinator 150˙000.00

Map

 Project objective

Anxiety and stress-related conditions represent a significant health burden in modern society. Anxiety disorders are currently treated with a variety of agents targeting synaptic mechanisms. These agents either directly affect neurotransmitter receptor systems or modulate neurotransmitter levels or availability, but their long-term use is limited by problematic side effects and suboptimal efficacy. The development of new anxiolytic drugs has been fraught with difficulty, hence there is a need for new targets and new avenues for therapeutic development.

Importin-dependent transport mechanisms link synapse to nucleus in a diversity of physiological contexts, rendering them potentially interesting targets for behavioural control. However importins and related molecules have not been evaluated for roles in anxiolysis to date. We discovered the roles of importins in axonal injury signaling and in cell size sensing. During the course of our current ERC Advanced grant, and as part of one of the aims, we have conducted comprehensive phenotyping of importin mouse mutants to identify in vivo consequences of the deregulation of size control pathways. One importin mutant line presented a specific phenotype in anxiety tests, and follow-up analyses identified a new molecular pathway for anxiety regulation, and approved drugs affecting this pathway that can be repositioned for anxiety treatment.

In this PoC, we will (1) carry out IP protection on our initial identifications of anxiolytic drugs; (2) further validate the anxiolytic activities of these drugs and their closely related structural or functional analogs; and (3) devise an HTS-compatible assay for targeting the importin involved and conduct a pilot screen of ~200,000 compounds in this assay to identify new drug leads for anxiety treatment. As a final step, we will carry out (4) additional IP protection and pre-commercialisation tasks for maximizing the commercialisation potential of our discovery.

 Publications

year authors and title journal last update
List of publications.
2018 Nicolas Panayotis, Anton Sheinin, Shachar Y. Dagan, Michael M. Tsoory, Franziska Rother, Mayur Vadhvani, Anna Meshcheriakova, Sandip Koley, Letizia Marvaldi, Didi-Andreas Song, Eitan Reuveny, Britta J. Eickholt, Enno Hartmann, Michael Bader, Izhak Michaelevski, Mike Fainzilber
Importin α5 Regulates Anxiety through MeCP2 and Sphingosine Kinase 1
published pages: 3169-3179.e7, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2018.11.066
Cell Reports 25/11 2019-09-04

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FAITH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FAITH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ERC VP CSA (2018)

Support to the Vice-Presidents of the ERC Scientific Council 2018

Read More  

CELPRED (2020)

Circuit elements of the cortical circuit for predictive processing

Read More  

CohoSing (2019)

Cohomology and Singularities

Read More